Last reviewed · How we verify
NCT03457506
Intra-individual Comparison of Conventional and Digital PET/CT Scanners
NA trial testing Digital PET/CT scan in Breast Cancer in 225 participants. Completed in 13 September 2019.
13 September 2019
Quick facts
| Lead sponsor | Isala |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 225 |
| Start date | 8 January 2018 |
| Primary completion | 13 September 2019 |
| Estimated completion | 13 September 2019 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Digital PET/CT scan
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Lung Cancer — all drugs for Lung Cancer →
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Miscellaneous Neoplasm — all drugs for Miscellaneous Neoplasm →
Sponsor
Isala — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
SUV variability in EARL-accredited conventional and digital PET.
Koopman D, Jager PL, Slump CH, Knollema S, et al · · 2019 · cited 22× · PMID 31823097 · DOI 10.1186/s13550-019-0569-7
Verify or expand the search:
- PubMed search for NCT03457506
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Digital PET/CT scan
Trials testing the same drug.
- NCT03081767 — Standard PET/CT vs. Digital PET/CT · NA · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Isala trials
Trials by the same sponsor.
- NCT06342843 — Direct Superior Approach Versus PosteroLateral Approach in Total Hip Arthroplasty (SPLAsH) · NA · recruiting
- NCT05682027 — Ultrasound as Diagnostic Tool in Diaphragm Dysfunction · completed
- NCT05860686 — Does Post-operative Rinsing With a Monoject Syringe Result in as Much Post-operative Pain After Surgical Removal of Lowe · NA · unknown
- NCT05180955 — The Role of Clamping Before Removal of a Pneumothorax Drain Connected to a Digital Drainage System. · NA · completed
- NCT05420974 — NIR Arthroscopic Fluorescence Angiography of Menisci · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03457506 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Isala
- Last refreshed: 19 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03457506.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing